Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer. Though the field has a lot of intuitive appeal, harnessing the body's own immune system to fight cancer with the hope of sustained effect and a very mild side effect profile, proven benefits of immunotherapy in cancer have been slow to come. But in the last few years, we've seen new treatments with impressive survival benefits in prostate cancer, melanoma, and others...while in lung cancer, the key studies are being conducted but have yet to report out.
Dr. Govindan covered the big topics of MAGE-A3, Stimuvax, and Lucanix in his part of the program. The audio and video versions of the podcast are below, along with the transcript and figures.
Govindan Immunotherapies in LC Part 1 Audio Podcast
Govindan Immunotherapies for LC Part 1 Transcript
Govindan Immunotherapies in LC Part 1 Figs
Part 2, featuring Dr. Brahmer, is being edited now and will be available soon. This includes some discussion of the research into the anti-PD1 vaccine that emerged as one of the most exciting stories in lung cancer from ASCO 2012, so look for that here soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.